PAWS-GIST awarded the National Cancer Research Institute’s Collaboration excellence award 2019!

We are really excited to announce that our PAWS GIST (Paediatric Adolescent Wild-type & Syndromic GIST) alliance has been awarded the National Cancer Research Institute‘s “Collaboration award”. This award recognises our unique European multidisciplinary team of patients, doctors, specialists and researchers who are collaborating to improve treatments and working to find a cure for PAWS-GIST cancer. The nominations […]

Continue reading

NHS England launches National Sarcoma Service Specification incorporating National GIST Guidelines

NHS England has published the long awaited National Sarcoma Service Specification which incorporates the National GIST guidelines and is designed to clearly state who should be managing GIST and Sarcoma patient care. This is the first time that Sarcoma and GIST services have been commissioned to deliver care to patients across England and follows many […]

Continue reading

GIST in Cancer52’s “Getting a better deal for Rare and Less Common Cancers report launched today…..

Today ,Cancer52 launched their  “Getting a better deal for Rare Cancers Report“ at the House of Commons in London. Included in the report were rare cancer patient case studies including the case of our very own GIST patient, Stephen Palmer (pictured right), who features throughout the report and whose case study is detailed on page 14. […]

Continue reading
GIST Trustees

Introducing GIST Support UK’s Brand new Website!

We are delighted to mark GIST Support UK’s 10th Anniversary in 2019 with the launch of our brand new website! Our work to support patients and stimulate research for improved treatments and a cure for GIST cancer continues and our address remains the same www.gistsupportuk.com. We hope that you like the new design. With very […]

Continue reading

News from ASCO 2019

Blueprint Medicines announced data from their registration-enabling NAVIGATOR trial of avapritinib in patients with PDGFRA Exon 18 mutant GIST and fourth-line GIST.   These results were presented at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting and will form the basis for planned worldwide marketing applications for avapritinib. The data demonstrate clinical activity […]

Continue reading